HDT 401
Alternative Names: HDT-401Latest Information Update: 02 Aug 2022
At a glance
- Originator HDT Bio
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action DDX58 protein stimulants; Toll-like receptor 3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Head and neck cancer
Most Recent Events
- 26 Jul 2022 Preclinical trials in Head and neck cancer in USA (Parenteral), prior to July 2022 (HDT Bio pipeline, July 2022)